Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00315640
Other study ID # C-05-03
Secondary ID 2005-001598-93
Status Completed
Phase Phase 2
First received April 17, 2006
Last updated November 27, 2012
Start date December 2005
Est. completion date July 2009

Study information

Verified date January 2010
Source Alcon Research
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date July 2009
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Either gender

- 18 years of age or older

- IOP elevation caused by steroid usage

- Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

- Under 18 years of age

- Other protocol-defined exclusion criteria may apply

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Anecortave Acetate Sterile Suspension, 6 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Suspension Depot, 30 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Anecortave Acetate Sterile Suspension, 60 mg/mL
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Other:
Anecortave Acetate Vehicle
One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Locations

Country Name City State
Brazil San Paulo San Paulo
Hungary Budapest Budapest
Italy Padova Padova
Netherlands Amsterdam Amsterdam
Puerto Rico Bayamon Bayamon
Spain Barcelona Barcelona
United Kingdom Newcastle upon Tyne Newcastle upon Tyne
United States Detroit Detroit Michigan
United States Houston Houston Texas
United States Jacksonville Jacksonville Florida
United States Miami Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Alcon Research

Countries where clinical trial is conducted

United States,  Brazil,  Hungary,  Italy,  Netherlands,  Puerto Rico,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in IOP at Week 4 from Baseline Week 4 No
See also
  Status Clinical Trial Phase
Recruiting NCT05414994 - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Completed NCT02811692 - Study for Collection of Aflibercept Data in Routine Practice
Recruiting NCT06045299 - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia Phase 3
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT04799704 - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting NCT05876689 - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Recruiting NCT04150432 - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Completed NCT02332343 - Sparing of the Fovea in Geographic Atrophy Progression N/A
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT00333203 - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study Phase 3
Not yet recruiting NCT05565547 - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Completed NCT05211089 - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases